DIMENSION
@_DimensionCap
Followers
2K
Following
692
Media
18
Statuses
308
A first-of-its-kind firm partnering with founders at the interface of technology and life sciences to transform the trajectory of life on earth
New York and San Francisco
Joined June 2022
Reflecting on 2024: a category sweep of the Nobels, AI enabled clinical readouts, and the first trillion dollar pharma in sight. We stand on the shoulders of giants. Looking to 2025: This is just the beginning. Make no small plans.
5
11
40
RT @zavaindar: The ACHIRA team is cracked. And, now, for the first time, they have public openings for: - ML Researchers - GPU "make go b…
jobs.ashbyhq.com
Achira Jobs
0
1
0
.@newlimit has raised an additional $45M from new investors including Lilly Ventures, Duke University, @S32_VC, @AbstractVC & others. Insiders including @kleinerperkins, @_DimensionCap, @humancapital, @BoostVC also participated. This round was catalyzed by technical
32
45
430
Last week, @RehaMathur (@_DimensionCap) and I hosted a dinner at MIT to bring together old and new friends working at the frontier of AI for life sciences. Evenings like this remind me how fortunate I am to have so many bright friends working to improve the world using science.
2
4
52
The best part about working on @modal is watching our customers literally build the future. Today, they’re using @modal for everything from generating AI music to powering real-world robots to curing cancer. And yet, this is just the beginning. We have so much more to build.
It's true – @modal has raised a $87M Series B at a $1.1B valuation to advance the future of AI infrastructure. Thank you to @Lux_Capital, @Redpoint, @AmplifyPartners, and others. Now more than ever, AI demands a complete reinvention of traditional compute infrastructure
21
18
288
portfolio++;
our most cutting edge companies are consistently @modal power users now, @_DimensionCap is also a proud Modal investor. thrilled to join @bernhardsson & @akshat_b on their quest to reimagine infrastructure in the age of AI!!
1
1
3
🚀 Chai Discovery has been named to the Endpoints News 11 list of the most promising biotech companies of 2025!
1
7
13
More BIG news from @MonteRosaTx: $120M upfront for up to 3 undisclosed preclinical programs in I&I, with up to $5.7B in preclinical, clinical, reg and sales milestones. Monte Rosa's publicly disclosed pipeline does not change, Novartis is paying for not yet public programs.
Big news from @MonteRosaTx ($GLUE) today: $150M upfront, $2.1B in milestones, and 30% US P&L share for VAV1 targeting numerous multibillion I&I indications Our writing on $GLUE from a $100M financing we led in May, below Congrats to @markus_warmuth and the entire team!
1
4
23
Excited to announce @_DimensionCap's partnership with @garydglick and the entire @Odyssey_Tx team on an oversubscribed Series D. They are moving ahead to an exciting chapter where the company will translate multiple programs out of a massively productive discovery platform.
Today, we announce the closing of a $213M Series D financing round. Thank you to our investors for supporting the advancement of our portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. https://t.co/bzVOFBMGyF
1
7
14
I'm thrilled that @_DimensionCap is leading @Odyssey_Tx's $213M Series D as they advance their pipeline through clinical trials. I've learned so much about immunology and inflammation over the past year, in large part due to Gary and his inimitable team at Odyssey. This is a
Today, we announce the closing of a $213M Series D financing round. Thank you to our investors for supporting the advancement of our portfolio of clinical and preclinical medicines designed to precisely treat the drivers of complex autoimmune diseases. https://t.co/bzVOFBMGyF
1
4
26
More on the @_DimensionCap co-led Series D for @Odyssey_Tx, one of the largest oversubscribed private rounds for therapeutics in 2025 (still possible!). Incredible team, technology, pipeline, and translational data. 🚀🚀🚀 https://t.co/vjc3W8PzS5
1
4
16
@_DimensionCap's research team will be at the @KeystoneSymp symposium on AI + Molecular Biology on Sept. 15th in Sante Fe. If you're there and would like to meet up, DM me or my colleague @bauer_lesavage. Hope to see you there!
0
3
12
Central nervous system (CNS) disorders are the leading cause of disease burden worldwide. Collectively, they affect 43% of the global population and are responsible for 443M disability adjusted life years (i.e. years lost to disability or premature death) each year. However,
5
4
33
We’ve been spending a lot of time recently in neurology. It’s a space in dire need of novel targets and drug mechanisms. Check out @bauer_lesavage’s newest essay on why neuro is so hard and what learnings we can reapply from biotech’s recent successes in immunology.
Central nervous system (CNS) disorders are the leading cause of disease burden worldwide. Collectively, they affect 43% of the global population and are responsible for 443M disability adjusted life years (i.e. years lost to disability or premature death) each year. However,
1
3
22
cannot wait for the next 12 months @viswacolluru and the entire @lifeschemistry team!!
endpoints.news
Enveda hit the $1 billion valuation milestone after reeling in another megaround on Thursday.
0
3
11
in the last 12 months Enveda has 1. entered the clinic w soon to be 3 new molecules 2. followed the science pursuing medicines with decacorn potential whilst altering billions of global lives 3. added Mikael Dolsten, former CSO of Pfizer, to the board 4. become a biotech unicorn
5
11
78
RT @zavaindar: i'd use this space to talk about Dimension portco @newlimit but having just watched the below w @jacobkimmel & @dwarkesh_sp…
0
1
0
🧬 Dr. Mikael Dolsten is joining the @ChaiDiscovery board! In 15 years as @Pfizer's Chief Scientific Officer he: ⚛️ Progressed 150 molecules to clinical trials 💊 Delivered 36 approved medicines, from vaccines to cancer therapies
4
12
109
.@dwarkesh_sp has a rare talent for traversing the tree of ideas by stepping upon only the most entropic branches it was a joy to discuss ideas around AI in bio, human evolution, the biology of aging, @newlimit, & the future of therapeutics a few weeks back
.@jacobkimmel thinks he can find the transcription factors necessary to reverse aging. 0:00:00 – Three reasons evolution didn't optimize for longevity 0:12:48 – Why didn't humans evolve their own antibiotics? 0:26:08 – De-aging cells via epigenetic reprogramming 0:45:24 – Viral
18
40
367